Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NISHANT GUPTA

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1487848875
CMS profile
1060543
Location
CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$109.56

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $109.56 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Biosense Webster, Inc. $109.56 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NISHANT GUPTA

NPI 1487848875 · CMS profile ID 1060543

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1487848875?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NISHANT GUPTA, NPI 1487848875, CMS profile ID 1060543. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487848875?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). NISHANT GUPTA, NPI 1487848875, CMS profile ID 1060543. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487848875?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
NISHANT GUPTA, NPI 1487848875, CMS profile ID 1060543, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1487848875?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $109.56 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biosense Webster, Inc. $109.5601/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718878983 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $411.88 3
PY2020 $109.56 1
PY2021 $2.50 1
PY2022 $338.12 1
PY2023 $12,022.52 6
PY2025 $740.51 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $566,381.76 128
PY2024 Principal investigator $319,780.15 66
PY2023 Principal investigator $287,438.24 47
PY2022 Principal investigator $204,112.69 28
PY2021 Principal investigator $29,775.29 8
PY2020 Principal investigator $82,388.01 22
PY2019 Principal investigator $40,600.47 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Roche Products Limited $6,202.80 12/29/2022 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM 151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS No dispute reported 06/30/2026 950697637
Principal investigator 1 United Therapeutics Corporation $4,309.20 12/28/2022 Non-covered Recipient Entity
University of Cincinnati Physicians
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 957807853
Principal investigator 1 Roche Products Limited $6,404.40 12/08/2022 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM 151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS No dispute reported 06/30/2026 950697819
Principal investigator 1 United Therapeutics Corporation $4,465.80 12/07/2022 Non-covered Recipient Entity
University of Cincinnati Physicians
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 957807851
Principal investigator 1 Roche Products Limited $14,749.20 12/06/2022 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM 151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS No dispute reported 06/30/2026 950697643
Principal investigator 1 Boehringer Ingelheim International GmbH $1,560.22 10/31/2022 Non-covered Recipient Entity
University Of Cincinnati
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 946884915
Principal investigator 1 Boehringer Ingelheim International GmbH $761.65 10/31/2022 Non-covered Recipient Entity
University Of Cincinnati
PDE4 Phase III trial in PF ILD No dispute reported 06/30/2026 946884921
Principal investigator 1 Roche Products Limited $2,847.60 10/20/2022 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM 151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS No dispute reported 06/30/2026 950709317
Principal investigator 1 CSL Behring $855.57 10/19/2022 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 940345513
Principal investigator 1 Roche Products Limited $4,527.00 09/19/2022 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM 151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS No dispute reported 06/30/2026 950712277
Principal investigator 1 Celgene Corporation $150.00 09/09/2022 Non-covered Recipient Entity
University Of Cincinnati Physicians Company Llc
PH II IPF-001 - A Phase 2, 24-Week, Randomized, Double-blind, Placebo-controlled, Multicenter Study, with an 80-Week Active Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects with Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 937183879
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,813.88 08/26/2022 Non-covered Recipient Entity
UC Health System
Extension No dispute reported 06/30/2026 949200248
Principal investigator 1 Roche Products Limited $16,575.00 08/08/2022 Non-covered Recipient Entity
UC HEALTH
TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM 151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS No dispute reported 06/30/2026 950712211
Principal investigator 1 United Therapeutics Corporation $9,625.00 07/27/2022 Non-covered Recipient Entity
University of Cincinnati Physicians
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 957806153
Principal investigator 1 United Therapeutics Corporation $7,348.05 07/27/2022 Non-covered Recipient Entity
University of Cincinnati Physicians
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 957806155
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,456.00 07/25/2022 Non-covered Recipient Entity
University Of Cincinnati
DCRI Registry Study No dispute reported 06/30/2026 949197355
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,336.80 06/29/2022 Non-covered Recipient Entity
University Of Cincinnati
DCRI Registry Study No dispute reported 06/30/2026 949200933
Principal investigator 1 CSL Behring $625.00 06/29/2022 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 940345299
Principal investigator 1 CSL Behring $2,300.00 06/29/2022 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 940345301
Principal investigator 1 CSL Behring $3,375.00 06/29/2022 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 940345303
Principal investigator 1 CSL Behring $3,645.00 06/29/2022 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 940345305
Principal investigator 1 CSL Behring $16,200.00 06/29/2022 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 940345307
Principal investigator 1 CSL Behring $3,375.00 06/29/2022 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 940345343
Principal investigator 1 United Therapeutics Corporation $8,517.15 06/29/2022 Non-covered Recipient Entity
University of Cincinnati Physicians
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 957806137
Principal investigator 1 United Therapeutics Corporation $12,636.00 06/08/2022 Non-covered Recipient Entity
University of Cincinnati Physicians
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 957806135
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,000.00 06/03/2022 Non-covered Recipient Entity
University of Cincinnati Physicians LLC
Pulmonary Rehabilitation and Nintedanib in IPF No dispute reported 06/30/2026 949196715
Principal investigator 1 CSL Behring $623.21 03/08/2022 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 940345477
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $46,828.16 01/27/2022 Non-covered Recipient Entity
University Of Cincinnati
Phase II Pulmonary Fibrosis Add-On and Treatment Nave No dispute reported 06/30/2026 933191385